// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Rationale and Design of Classic-MS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets

Alexey Boyko - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine Treated Patients at the 96 Week Timepoint (CLARITY) Using Deconvolution Algorithms

Irina Kalatskaya - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Cladribine

An Analysis of the Relationship between Cladribine Dose and Risk of Malignancies in Patients with Multiple Sclerosis

Stuart Cook - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Long-Term Disease Stability Assessed By the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the Clarity and Clarity Extension Studies

Gavin Giovannoni - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

Cladribine

Integrated Lymphopenia Analysis in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets

Gavin Giovannoni - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Cladribine

Siponimod Affects Disability Progression in Patients with SPMS Independent of Relapse Activity: Results from the Phase 3 Expand Study

Bruce A C Cree - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Siponimod

Determining the Relationship of Demographic and Clinical Variables with Fatigue in Multiple Sclerosis, Using the 5 Item Modified Fatigue Impact Scale (MFIS-5)

Natasha Hameed - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

The Impact of Vascular Comorbidities on Perceived Functional Impact in Persons with Multiple Sclerosis

Elizabeth S Gromisch - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Predicting Fall Risk in Persons with Multiple Sclerosis Utilizing the 12-Item Multiple Sclerosis Walking Scale

Heather M DelMastro - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

The Impact of Lower Limb Strength on Walking in Persons with Multiple Sclerosis: A Preliminary Analysis

Heather M DelMastro - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

MS Brain Health Global Quality Standards: MS Nurses' Role in Development and Implementation

Amy Bowen - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effectiveness, Safety and PROs of Ofatumumab in RMS Patients Switching from Dimethyl Fumarate or Fingolimod: Artios Phase 3b Study Design

Matthew Craner - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Depression

Dimethyl fumarate

Development and Usability Testing of a Patient-Based Digital Tool to Detect Early Signs of Changes in Multiple Sclerosis Symptoms and Progression: Your MS Questionnaire

Tjalf Ziemssen - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

International Magnims-CMSC-Naims Consensus Recommendations on the Use of Standardized MRI in MS

Anthony Traboulsee - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Spasticity Experience in Adults with Multiple Sclerosis: An Integrated Conceptual Model

Michelle H. Cameron - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years

Bruce A.C. Cree - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Siponimod

Long-Term Efficacy and Safety of Eculizumab in AQP4+ Neuromyelitis Optica Spectrum Disorder

Dean Wingerchuk - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Neuromyelitis optica

Eculizumab

Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: Findings from Prevent

Michael Levy - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Neuromyelitis optica

Intratect

Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years

Douglas L. Arnold - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Siponimod

Relationship of Functional Outcomes and Routinely Performed MRI Studies in Persons with Multiple Sclerosis: An Insight into the Frontal Lobe Structural Alterations

Zaenab Dhari - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Copyright © 2026. QuantiNova All rights reserved